Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Gastric04 in HER2-positive metastatic or unresectable gastric/GEJ adenocarcinoma after trastuzumab
jRCT2031200369Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Trastuzumab deruxtecan with Ramucirumab + paclitaxel (2 arms). Primary endpoint: Overall survival. Started May 2021; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecanramucirumabpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2031200369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200369.